The NDA submission timeline for rezatapopt in Q1 2027 is the primary catalyst. Monitor for any data readouts or regulatory updates from the PYNNACLE trial that could derail or accelerate the filing.
Price Chart
Executive Summary
PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, with the press release also announcing the company plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027. The appointment of a healthcare investor with public/private market experience is a routine board addition, but the NDA timeline provides a concrete near-term catalyst for the stock.
Key Facts
- Dr. Matthew Eckler appointed to the Board of Directors on October 1, 2026.
- Eckler is a Principal at Samsara BioCapital, with prior healthcare investing roles at ArrowMark Partners and GMT Capital.
- Company plans to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in Q1 2027.
- Rezatapopt targets TP53 Y220C mutations in platinum-resistant/refractory ovarian cancer.
- FDA granted Fast Track designation and Orphan Drug Designation for rezatapopt.
- Enrollment in the Phase 2 monotherapy portion of the PYNNACLE trial has been completed.
- Eckler received an initial stock option award for 84,000 shares and $40,000 annual cash compensation.
Financial Impact
No financial figures disclosed; the NDA submission timeline is the key catalyst.
Risk Factors
- NDA submission and subsequent FDA approval are not guaranteed; clinical data may not support accelerated approval.
- Rezatapopt is a single-product pipeline company; any regulatory setback would be material.
- The company's ability to fund operations through potential commercialization is not addressed in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-413254 |
| Document: d174662dex991.htm | 0001193125-26-413254 |
| Document: 0001193125-26-413254-index-headers.html | 0001193125-26-413254 |
| Document: 0001193125-26-413254-index.html | 0001193125-26-413254 |
| Document: 0001193125-26-413254.txt | 0001193125-26-413254 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.52%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers